Abstract
In this study, we investigated the protein expression of platelet-derived growth factor receptor (PDGFR), insulin like growth factor-1 receptor (IGF-1R), phosphatidylinositol 3-kinase (PI3-K) and extracellular signal-regulated kinase (ERK1/2) in five primary glioblastoma (GB), with a view to their possible use as therapeutic targets. Our results demonstrated that appreciable levels of these proteins could be detected in the analysed GB cell lines, except for a low level of PDGFR and ERK1/2 expression in one GB cell line. The small molecule inhibitors towards IGF-1R, PDGFR, PI3-K and ERK1/2 respectively, have only modest or no anti-tumour activity on GB cells and therefore their combination with other therapy modalities was analysed. The interaction between small inhibitors and radiation was mostly additive or sub-additive; synergistic interaction was found in five of forty analysed combinations. Our results showed that GB cells are in general resistant to treatment and illustrate the difficulties in predicting the treatment response in malignant gliomas.
Similar content being viewed by others
Abbreviations
- IGF-1R:
-
Insulin like growth factor-1 receptor
- PDGFR:
-
Platelet derived growth factor receptor
- PI3-K:
-
Phosphatidylinositol 3-kinase
- MEK:
-
Mitogen/extracellular signal-regulated kinase
- ERK:
-
Extracellularsignal-regulated kinase
- GB:
-
Glioblastoma
References
Allalunis-Turner MJ, Zia PK, Barron GM, Mirzayans R, Day RSIII (1995) Radiation-induced DNA damage and repair in cells of a radiosensitive human malignant glioma cell line. Radiat Res 144:288–293. doi:10.2307/3578948
Anderson CW, Dunn JJ, Freimuth PI, Galloway AM, Allalunis-Turner MJ (2001) Frameshift mutation in PRKDC, the gene for DNA-PKcs, in the DNA repair-defective, human, glioma-derived cell line M059J. Radiat Res 156:2–9. doi:10.1667/0033-7587(2001)156[0002:FMIPTG]2.0.CO;2
Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, Baserga R, Iliakis G, Aiken RD (2001) Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19:2189–2200
Antoniades HN, Galanopoulos T, Neville-Golden J, Maxwell M (1992) Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 50:215–222. doi:10.1002/ijc.2910500210
Backlund LM, Nilsson BR, Goike HM, Schmidt EE, Liu L, Ichimura K, Collins VP (2003) Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 9:4151–4158
Backlund LM, Nilsson BR, Liu L, Ichimura K, Collins VP (2005) Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer 93:124–130. doi:10.1038/sj.bjc.6602661
Baserga R, Sell C, Porcu P, Rubini M (1994) The role of the IGF-I receptor in the growth and transformation of mammalian cells. Cell Prolif 27:63–71. doi:10.1111/j.1365-2184.1994.tb01406.x
Bridle KR, Li L, O’Neill R, Britton RS, Bacon BR (2006) Coordinate activation of intracellular signaling pathways by insulin-like growth factor-1 and platelet-derived growth factor in rat hepatic stellate cells. J Lab Clin Med 147:234–241. doi:10.1016/j.lab.2005.12.009
Brodt P, Samani A, Navab R (2000) Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 60:1101–1107. doi:10.1016/S0006-2952(00)00422-6
Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657. doi:10.1126/science.296.5573.1655
Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200–207
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55. doi:10.1016/0065-2571(84)90007-4
Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A (2007) Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 26:2423–2434. doi:10.1038/sj.onc.1210037
Del Valle L, Enam S, Lassak A, Wang JY, Croul S, Khalili K, Reiss K (2002) Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res 8:1822–1830
DiBiase SJ, Zeng ZC, Chen R, Hyslop T, Curran WJ Jr, Iliakis G (2000) DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res 60:1245–1253
Dimova EY, Moller U, Herzig S, Fink T, Zachar V, Ebbesen P, Kietzmann T (2005) Transcriptional regulation of plasminogen activator inhibitor-1 expression by insulin-like growth factor-1 via MAP kinases and hypoxia-inducible factor-1 in HepG2 cells. Thromb Haemost 93:1176–1184
Dricu A, Carlberg M, Wang M, Larsson O (1997) Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis. Cancer Res 57:543–548
Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550–4553
Fomchenko EI, Holland EC (2007) Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. Neurosurg Clin N Am 18:39–58, viii. doi:10.1016/j.nec.2006.10.006
Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D, Hassan AB (2005) Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205:145–153. doi:10.1002/path.1712
Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193–204. doi:10.1016/j.ctrv.2003.07.007
Froesch ER, Schmid C, Schwander J, Zapf J (1985) Actions of insulin-like growth factors. Annu Rev Physiol 47:443–467. doi:10.1146/annurev.ph.47.030185.002303
Germano IM, Ito M, Cho KG, Hoshino T, Davis RL, Wilson CB (1989) Correlation of histopathological features and proliferative potential of gliomas. J Neurosurg 70:701–706
Grossman SA, Batara JF (2004) Current management of glioblastoma multiforme. Semin Oncol 31:635–644. doi:10.1053/j.seminoncol.2004.07.005
Hagerstrand D, Hesselager G, Achterberg S, Wickenberg Bolin U, Kowanetz M, Kastemar M, Heldin CH, Isaksson A, Nister M, Ostman A (2006) Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 25:4913–4922. doi:10.1038/sj.onc.1209497
Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR (2006) Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32:74–89. doi:10.1016/j.ctrv.2006.01.003
Han VK, D’Ercole AJ, Lund PK (1987) Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 236:193–197. doi:10.1126/science.3563497
Hanada M, Feng J, Hemmings BA (2004) Structure, regulation and function of PKB/AKT—a major therapeutic target. Biochim Biophys Acta 1697:3–16
Hoppe BS, Jensen RB, Kirchgessner CU (2000) Complementation of the radiosensitive M059J cell line. Radiat Res 153:125–130. doi:10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2
Jiang R, Mircean C, Shmulevich I, Cogdell D, Jia Y, Tabus I, Aldape K, Sawaya R, Bruner JM, Fuller GN, Zhang W (2006) Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 6:2964–2971. doi:10.1002/pmic.200500555
Johnson TR, Trojan J, Anthony DD, Rudin SD, Tykocinski ML, Ilan J, Ilan J (1994) Gene therapy of rat brain glioblastoma by an episome-based transcriptional cassette expressing antisense IGF-I cDNA. Indian J Biochem Biophys 31:1–13
Kasprzak HA, Trojan J, Bierwagen M, Kopinski P, Jarocki P, Bartczak K, Czapiewska J (2006) [Usefulness of the antisense and triplex anti-IGF-1 techniques for postoperative cellular gene therapy of malignant gliomas expressing IGF-1]. Neurol Neurochir Pol 40:509–515 (discussion 516)
Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244. doi:10.1210/er.21.3.215
Kiess W, Lee L, Graham DE, Greenstein L, Tseng LY, Rechler MM, Nissley SP (1989) Rat C6 glial cells synthesize insulin-like growth factor I (IGF-I) and express IGF-I receptors and IGF-II/mannose 6-phosphate receptors. Endocrinology 124:1727–1736
Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O’Reilly T, Buchdunger E, Black PM, Stiles CD (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60:5143–5150
Kurmasheva RT, Houghton PJ (2006) IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766:1–22
Lees-Miller SP, Godbout R, Chan DW, Weinfeld M, Day RSIII, Barron GM, Allalunis-Turner J (1995) Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science 267:1183–1185. doi:10.1126/science.7855602
Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729–3735
Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292. doi:10.1002/path.1706
Ly A, Duc HT, Kalamarides M, Trojan LA, Pan Y, Shevelev A, Francois JC, Noel T, Kane A, Henin D, Anthony DD, Trojan J (2001) Human glioma cells transformed by IGF-I triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma. Mol Pathol 54:230–239. doi:10.1136/mp.54.4.230
MacKeigan JP, Taxman DJ, Hunter D, Earp HSIII, Graves LM, Ting JP (2002) Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase inhibition. Clin Cancer Res 8:2091–2099
Martin DM, Yee D, Carlson RO, Feldman EL (1992) Gene expression of the insulin-like growth factors and their receptors in human neuroblastoma cell lines. Brain Res Mol Brain Res 15:241–246. doi:10.1016/0169-328X(92)90114-Q
Mauro A, Di Sapio A, Mocellini C, Schiffer D (1995) Control of meningioma cell growth by platelet-derived growth factor (PDGF). J Neurol Sci 131:135–143. doi:10.1016/0022-510X(95)00106-C
Mrugala MM, Kesari S, Ramakrishna N, Wen PY (2004) Therapy for recurrent malignant glioma in adults. Expert Rev Anticancer Ther 4:759–782. doi:10.1586/14737140.4.5.759
Nathoo N, Goldlust S, Vogelbaum MA (2004) Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas. Neurosurgery 54:1480–1488. doi:10.1227/01.NEU.0000125006.88478.F6 (discussion 1488–1489)
Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R (2006) Epidermal growth factor receptor—mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 12:7261–7270. doi:10.1158/1078-0432.CCR-06-0874
Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14:381–395. doi:10.1016/S0898-6568(01)00271-6
Ozaki K (2007) Targeted molecular strategies for cancer therapy based on the blockade of oncogenic pathways in human tumor cells. Yakugaku Zasshi 127:983–991. doi:10.1248/yakushi.127.983
Perer ES, Madan AK, Shurin A, Zakris E, Romeguera K, Pang Y, Beech DJ (2000) Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res 94:1–5. doi:10.1006/jsre.2000.5923
Ponten J, Westermark B (1978) Properties of human malignant glioma cells in vitro. Med Biol 56:184–193
Pulkkanen KJ, Yla-Herttuala S (2005) Gene therapy for malignant glioma: current clinical status. Mol Ther 12:585–598. doi:10.1016/j.ymthe.2005.07.357
Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R (1994) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 54:2218–2222
Resnicoff M, Li W, Basak S, Herlyn D, Baserga R, Rubin R (1996) Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Cancer Immunol Immunother 42:64–68. doi:10.1007/s002620050252
Sandberg-Nordqvist AC, Stahlbom PA, Reinecke M, Collins VP, von Holst H, Sara V (1993) Characterization of insulin-like growth factor 1 in human primary brain tumors. Cancer Res 53:2475–2478
Sanson M, Laigle-Donadey F, Benouaich-Amiel A (2006) Molecular changes in brain tumors: prognostic and therapeutic impact. Curr Opin Oncol 18:623–630. doi:10.1097/01.cco.0000245322.11787.72
Schmidberger H, Rave-Frank M, Lehmann JJ, Weiss E, Gerl L, Dettmer N, Glomme S, Hess CF (2003) Lack of interferon beta-induced radiosensitization in four out of five human glioblastoma cell lines. Int J Radiat Oncol Biol Phys 55:1348–1357. doi:10.1016/S0360-3016(02)04575-3
Shamah SM, Stiles CD, Guha A (1993) Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 13:7203–7212
Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A, Zha J, Forrest WF, Nigro JM, Modrusan Z, Feuerstein BG, Phillips HS (2007) Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci USA 104:3466–3471. doi:10.1073/pnas.0611271104
Sourbier C, Lindner V, Lang H, Agouni A, Schordan E, Danilin S, Rothhut S, Jacqmin D, Helwig JJ, Massfelder T (2006) The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res 66:5130–5142. doi:10.1158/0008-5472.CAN-05-1469
Strawn LM, Mann E, Elliger SS, Chu LM, Germain LL, Niederfellner G, Ullrich A, Shawver LK (1994) Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor. J Biol Chem 269:21215–21222
Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial I, Anderson KC (2007) Targeting MEK induces myeloma cell cytotoxicity and inhibits osteoclastogenesis. Blood 110(5):1656–1663
Trojan J, Blossey BK, Johnson TR, Rudin SD, Tykocinski M, Ilan J, Ilan J (1992) Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA 89:4874–4878. doi:10.1073/pnas.89.11.4874
Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259:94–97. doi:10.1126/science.8418502
Trojan J, Duc HT, Upegui-Gonzalez LC, Hor F, Guo Y, Anthony D, Ilan J (1996) Presence of MHC-I and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA. Neurosci Lett 212:9–12. doi:10.1016/0304-3940(96)12770-1
Trojan LA, Kopinski P, Wei MX, Ly A, Glogowska A, Czarny J, Shevelev A, Przewlocki R, Henin D, Trojan J (2002) IGF-I: from diagnostic to triple-helix gene therapy of solid tumors. Acta Biochim Pol 49:979–990
Trojan LA, Kopinski P, Mazurek A, Chyczewski L, Ly A, Jarocki P, Niklinski J, Shevelev A, Trzos R, Pan Y, Gitis DJ, Bierwagen M, Czapiewska JL, Wei MX, Michalkiewicz J, Henin D, Popiela T, Evrard F, Kasprzak H, Anthony D, Trojan J (2003) IGF-I triple helix gene therapy of rat and human gliomas. Rocz Akad Med Bialymst 48:18–27
Trojan J, Cloix JF, Ardourel MY, Chatel M, Anthony DD (2007) Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 145:795–811. doi:10.1016/j.neuroscience.2007.01.021
Vassbotn FS, Andersson M, Westermark B, Heldin CH, Ostman A (1993) Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant. Mol Cell Biol 13:4066–4076
von Deimling A, Louis DN, Wiestler OD (1995) Molecular pathways in the formation of gliomas. Glia 15:328–338. doi:10.1002/glia.440150312
Wen B, Deutsch E, Marangoni E, Frascona V, Maggiorella L, Abdulkarim B, Chavaudra N, Bourhis J (2001) Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 85:2017–2021. doi:10.1054/bjoc.2001.2171
Wong ML, Kaye AH, Hovens CM (2007) Targeting malignant glioma survival signalling to improve clinical outcomes. J Clin Neurosci 14:301–308. doi:10.1016/j.jocn.2006.11.005
Wu CJ, Chen Z, Ullrich A, Greene MI, O’Rourke DM (2000) Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs). Oncogene 19:3999–4010. doi:10.1038/sj.onc.1203748
Yin D, Tamaki N, Parent AD, Zhang JH (2005) Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. Neurol Res 27:27–35. doi:10.1179/016164105X18151
Acknowledgments
Grant sponsor: European Commission grant QLGA-CT-2000-60005; Cancer and Allergy Foundation, Stockholm; CNMP 41–063 Bucharest; Swedish Society of Medicine and The National Board of Health and Welfare Stockholm.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carapancea, M., Alexandru, O., Fetea, A.S. et al. Growth factor receptors signaling in glioblastoma cells: therapeutic implications. J Neurooncol 92, 137–147 (2009). https://doi.org/10.1007/s11060-008-9753-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-008-9753-8